Literature DB >> 16003241

Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells.

Carla C Baan1, Barbara J van der Mast, Mariska Klepper, Wendy M Mol, Annemiek M A Peeters, Sander S Korevaar, Aggie H M M Balk, Willem Weimar.   

Abstract

BACKGROUND: The transcription factor FOXP3 has been identified as the molecule associated with the regulatory function of CD25+ T cells.
METHODS: To understand the biology of FOXP3+ T cells in allogeneic reactions, we measured FOXP3 mRNA expression levels in allostimulated CD25 cells and CD25 cells and in peripheral blood mononuclear cells (PBMC). The effect of immunosuppressive drugs on FOXP3 expression was studied in mixed lymphocyte reactions (MLR) in the presence and absence of calcineurin inhibitors (CNI), alphaCD25 mAb, and Rapamycin (Rapa), and analyzed in biopsies from cardiac allograft recipients during acute rejection by quantitative (Q)-PCR.
RESULTS: FOXP3 mRNA expression was restricted to the CD25 population that inhibited the proliferation of allostimulated CD25 cells. In the MLR FOXP3 was readily induced after allostimulation. Kinetic examination of the MLR showed a 10-20-fold higher FOXP3 mRNA expression level after 5 days of culture. The CNI Cyclosporin and Tacrolimus, and alphaCD25 mAb inhibited in vitro induced FOXP3 gene transcription (range 70%-90%), whereas Rapa did not inhibit the induction. After clinical heart transplantation the highest FOXP3 mRNA expression levels were measured in biopsies during acute rejection (P=0.03).
CONCLUSIONS: The high FOXP3 mRNA levels during allogeneic responses in vivo and in vitro suggests that regulatory activities of CD25 T cells or the generation of these cells is an intrinsic part of activation. CNI and alphaCD25 mAb in contrast to Rapa, did interfere with this immunosuppressive counter-mechanism and as a result might have an inhibitory effect to tolerance induction after transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003241     DOI: 10.1097/01.tp.0000164142.98167.4b

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  58 in total

Review 1.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

2.  Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.

Authors:  Marina Cetkovic-Cvrlje; Marin Olson; Ketaki Ghate
Journal:  Cell Mol Immunol       Date:  2012-06-25       Impact factor: 11.530

Review 3.  Immune profiling and cancer post transplantation.

Authors:  Christopher Martin Hope; Patrick Toby H Coates; Robert Peter Carroll
Journal:  World J Nephrol       Date:  2015-02-06

Review 4.  Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses.

Authors:  N Singh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267

Review 5.  Regulatory T-cell therapy in transplantation: moving to the clinic.

Authors:  Qizhi Tang; Jeffrey A Bluestone
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 6.  The effects of immunosuppression on regulatory CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation.

Authors:  Aqeel Javeed; Yong Zhao
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 7.  Histone deacetylase inhibitors and transplantation.

Authors:  Ran Tao; Edwin F de Zoeten; Engin Ozkaynak; Liqing Wang; Bin Li; Mark I Greene; Andrew D Wells; Wayne W Hancock
Journal:  Curr Opin Immunol       Date:  2007-08-24       Impact factor: 7.486

8.  Peripheral blood T regulatory cell counts may not predict transplant rejection.

Authors:  Yuchuan Huang; Juan Shan; Chuntao Zhang; Jie Zhang; Li Feng; Shengfu Li; Youping Li
Journal:  BMC Immunol       Date:  2010-07-15       Impact factor: 3.615

9.  Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study.

Authors:  Arnd Heiligenhaus; Beatrix Zurek-Imhoff; Martin Roesel; Maren Hennig; Daniela Rammrath; Carsten Heinz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-17       Impact factor: 3.117

10.  The role of basiliximab in the evolving renal transplantation immunosuppression protocol.

Authors:  Paola Salis; Chiara Caccamo; Roberto Verzaro; Salvatore Gruttadauria; Mary Artero
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.